The preparation of (E)-3-(aryl(arylamino)methylene)indolin-2-one derivatives is illustrated in Schemes 1-3. An acyl chloride obtained from compound 1 (prepared according to the literature [20] [21] [22] ) and SOCl 2 , reacted with morpholine, piperidine and N-methylpiperazine to give compounds 2a-c, which were then reduced to compounds 3a-c under H 2 /Pd-C.
Compounds 4a-d were reacted with benzaldehyde to give 5a-d in the presence of piperidine in ethanol. Compounds 6a-d were then prepared in high yields by adding bromine in dichloromethane to solutions of 5a-d in CH 2 Cl 2 (Scheme 2).
Compounds 6a-d were reacted with compounds 7a-c or 3a-c in DMF in the presence of NaHCO 3 to form the target compounds 8a-e or 9a-g, respectively (Scheme 3). The use of K 2 CO 3 as base in DMF was also studied, but gave either more impurities and lower yields or even no product at all. Dibromo-compound 6 was (E)-3-(Aryl(arylamino)methylene)indolin-2-one derivatives: an efficient synthetic approach and evaluation of their cancer inhibitory activity Hongwu A series of (E)-3-(aryl(arylamino)methylene)indolin-2-one derivatives were synthesised using an efficient synthetic approach. The method involved reaction of 3-bromo-3-(bromo(aryl)methyl)indolin-2-one with substituted anilines through nucleophilic substitution and a simultaneous elimination using NaHCO 3 in DMF. The anticancer activity of the products against four cell lines, HCT-116, A549, SKOV3 and MDA-MB-231, was also evaluated, and several compounds showed moderate inhibitory activity.
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first transformed into a vinyl bromide derivative, which was then reacted with 3 or 7 very slowly, but no product was obtained. The reaction proceeded very slowly due to the p-π conjugated system of the bromine atom and the C=C double bond for the intermediate of the 3-(bromo(phenyl)methylene)-indolin-2-one derivatives. As for compound 6, nucleophilic substitution happened more easily and faster between the bromoalkane with aniline, and then the elimination reaction proceeded to form the target compound.
In the H-H COSY NMR spectrum of compound 5b, the signal of H4 at 7.35 ppm interacted with the signal of H2′ at 7.72 ppm and that of H6′ at the phenyl group, indicating there existed an E configuration. Intermediate 6 has different possible stereoisomers that can be seen in the proton-NMR spectra, with signals of the NH of the indolinone and the CHBr double singlets. However, the existence of isomers does not affect the following reaction, as all raw materials are transferred to the product during the reaction. The proton-NMR signals of H4 in the indolinones of compounds 8 and 9 are located at greater than 7, according to the literature. 19 If their structures have the Z Scheme 1 Synthetic method for 2-(4-aminophenoxy)acetamide derivatives 3a-c.
Scheme 2 Synthetic pathway for 3-bromo-3-(bromo(phenylmethyl))-indolin-2-one derivatives 6a-d.
configuration, H4 will correlate with H2′ and H6′ of the phenyl group through NOE and the signal of H4 will be lower than 7.
In the H-H COSY NMR of compound 8d, the signal of H4 at 7.85 ppm interacted with the signal of H3′ at 6.58 ppm and that of H5′ of the anilino group, although the intramolecular hydrogen bond that can exist between the amino group and the carbonyl group will promote the formation of the Z configuration, the signal of H4 of our target compounds occurred at about 7.6 ppm and, as noted in the literature, 16 the signals of H4 of similar analogues are located at 5.7-5.9 ppm. Hence, we concluded that the E configuration products were formed during the reaction. All of the target compounds were easily purified by recrystallisation, and their structures were confirmed by 1 H NMR, 13 C NMR and ESI-MS.
Biological evaluation
The antitumour activity in vitro of compounds 8a-e and 9a-g was evaluated by the MTT assay and compared with that of the reference drug gefitinib. Four different cancer cell lines, Scheme 3 Synthetic pathway for target compounds 8a-e and 9a-g. human colonic cancer cell (HCT116), human lung cell (A549), human ovarian cancer cell (SKOV3) and human breast cancer cell (MAD-MB-231), were chosen to be tested. The results are presented in Table 1 .
As can be seen from the table, 8d and 8e showed good inhibitory activity against all four cells, 8c and 9e displayed better activity than gefitinib towards HCT116, 9d displayed the same activity as gefitinib towards HCT116, A549 and MDA-MB-231, 8e, 9a, 9e and 9g showed the same or better activity than gefitinib against MAD-MB-231, and only 8d and 8e showed moderate inhibitory activity against SKOV3. Other compounds showed either low or no inhibitory activity. It appears that the bromo group at position 5 of indolin-2-one promoted activity in compounds 8a-e, and compounds containing the piperidine group could increase the activity in compounds 9a-g.
Conclusion
An efficient approach to synthesising (E)-3-(aryl(arylamino) methylene)indolin-2-one derivatives was developed and 12 target compounds were obtained in good yields. Their antitumour activity in vitro was evaluated by the MTT assay, and the results show that the introduction of a bromine atom in the indolin-2-one and the piperidine-containing structure appears to increase their antitumour activity. This could provide a reference for new drug development.
Experimental
All reagents were purchased from commercial suppliers and were used without further purification unless otherwise specified. Melting points were determined by a capillary method and are uncorrected. IR spectra were recorded on a Spectrum Two Li10014 spectrometer. 1 H NMR and 13 C NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer. NMR spectra were recorded in DMSO-d 6 or CDCl 3 solutions at room temperature (20 ± 2 °C). 1 H and 13 C chemical shifts are quoted in parts per million (ppm) downfield from tetramethylsilane (TMS). ESI-MS spectra were recorded on a Bruker Esquire 3000 instrument. High-resolution mass spectra (HRMS) were obtained on a MicroTOF-Q II mass spectrometer with an ESI source (Waters, Manchester). All reactions were monitored by thinlayer chromatography (TLC) and using ultraviolet light (254 nm). As for the known compounds, melting points and 1 H NMR spectra were confirmed by comparison with data from the previously reported literature, and the main intermediates were characterised by IR, 1 H NMR, 13 C NMR and mass spectra.
Synthesis of N-2-(4-nitrophenoxy)acetamide derivatives (2a-c);
general procedure A mixture of compound 1 (10 mmol) and three drops of DMF in thionyl chloride (10 mL) was refluxed for 1.5 h. Thionyl chloride was evaporated under vacuum and CH 2 Cl 2 (20 mL) was added.
To a mixture of the heterocyclic aliphatic amine (12 mmol) and triethylamine (30 mmol) in CH 2 Cl 2 (50 mL) the acyl chloride solution was slowly added dropwise, with constant stirring and cooling of the reaction mixture using an ice-water bath. The mixture was then stirred for 30 min at room temperature, the organic layer was separated, washed twice with salt water, dried with anhydrous sodium sulfate, and the solvent was removed to give the crude product, which was recrystallised from ethanol to give compound 2. 
1-(Morpholin-4-yl)-2-(4-nitrophenoxy)ethanone

(M+H).
Synthesis of 2-(4-aminophenoxy)acetamide derivatives (3a-c);
general procedure Compound 2 (10 mmol) in ethanol (50 mL) was hydrogenated at 0.2-0.4 MPa, catalysed by 10% Pd-C at room temperature, and recrystallised from ethanol to yield compound 3. Synthesis of (E)-5-substituted-3-benzylideneindolin-2-one derivatives (5a-d); general procedure A mixture of compound 4 (10 mmol), benzaldehyde (12 mmol) and a few drops of piperidine in ethanol (100 mL) was refluxed for 2 h. Part of the solvent was evaporated under reduced pressure and the residue was cooled to room temperature to crystallise the solid product, which was filtered off, washed twice with ethanol, and dried to yield compound 5.
2-(4-Aminophenoxy
( 
Synthesis of 5-substituted-3-bromo-3-(bromo(phenyl)methyl)indolin-2-one derivatives (6a-d); general procedure
To a solution of compound 5 (5 mmol) in CH 2 Cl 2 (100 mL), bromine (10 mmol) was slowly added dropwise at 0-5 °C, and the solution was then stirred for 3 h at room temperature. Water (50 mL) was poured into the solution and the phase was separated. The organic layer was washed with sodium thiosulfate solution to remove the extra bromine and washed further with saturated salt water (30 mL) and dried with anhydrous sodium sulfate. The organic layer was evaporated under reduced pressure to give the crude product, which was then recrystallised from ethanol to give compound 6. (9a-g) ; general procedure A mixture of compounds 6 (0.25 mmol) and 7 (or 3) (0.3 mmol) and sodium bicarbonate (1.00 mmol) in DMF (50 mL) was reacted for 24 h at room temperature. The mixture was poured into water (30 mL), the solid was filtered off, washed with water, and recrystallised from methanol to yield compound 8 (or 9).
3-Bromo-3-(bromo(phenyl)methyl)indolin-2-one
Synthesis of (E)-5-substituted-3-(phenyl(phenylamino)methylene) indolin-2-one derivatives (8a-e) and (E)-5-substituted-3-(((4-heterocyclic-2-oxoethoxy)phenylamino)(phenyl)methylene)indolin-2-one derivatives
( ) were seeded in 96-well plates and cultured for 24 h, followed by treatment with various concentrations of the compounds ranging from 50 μM to 1.56 μM for 48 h at 37 °C under 5% CO 2 . Then, MTT (20 μL of 5 mg mL −1 ) was added to each well and incubated for another 4 h at 37 °C, the supernatant fluid was removed, and DMSO (150 μL per well) was added for 15-20 min. Values of light absorption (OD) were measured at 570 nm with a SpectraMAX M5 microplate spectrophotometer (Molecular Devices). Gefitinib (TN) was used as the reference drug for antitumour evaluation and was also assessed under similar conditions for comparison with the tested compounds. The response parameter calculated was the IC 50 value, which corresponds to the concentration required for 50% inhibition of cell viability. The data for the antibacterial activity are presented in Table 1 .
